tiprankstipranks
Global Health Limited (IN:MEDANTA)
:MEDANTA
India Market
Want to see IN:MEDANTA full AI Analyst Report?

Global Health Limited (MEDANTA) AI Stock Analysis

5 Followers

Top Page

IN:MEDANTA

Global Health Limited

(MEDANTA)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 5.2)
Rating:66Neutral
Price Target:
₹1,309.00
▲(7.59% Upside)
Action:Reiterated
Date:05/15/26
The score is driven primarily by strong fundamental growth and profitability trends, tempered by weaker cash-flow quality (negative free cash flow in 2026 and higher debt). Technical indicators are supportive, but a very high P/E meaningfully weighs on the overall rating.
Positive Factors
Consistent revenue growth
Sustained multi-year top-line expansion reflects growing patient volumes, higher occupancy and expanded service mix. This durable demand-driven growth supports scale economics, long-term investment returns and strengthens bargaining power with payers and suppliers over the next several quarters.
Negative Factors
Negative free cash flow in 2026
A shift to negative FCF signals higher capex or working capital needs that weaken near-term liquidity and reduce internal funding for growth. If sustained, negative FCF may force external financing, increase cost of capital, and constrain discretionary investment over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Sustained multi-year top-line expansion reflects growing patient volumes, higher occupancy and expanded service mix. This durable demand-driven growth supports scale economics, long-term investment returns and strengthens bargaining power with payers and suppliers over the next several quarters.
Read all positive factors

Global Health Limited (MEDANTA) vs. iShares MSCI India ETF (INDA)

Global Health Limited Business Overview & Revenue Model

Company Description
Global Health Limited, a multi-specialty tertiary care provider, offers healthcare services in India. The company primarily offers treatments in the areas of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary scie...
How the Company Makes Money
Global Health Limited primarily makes money by delivering hospital-based healthcare services to patients. The core revenue stream is patient service income from (1) inpatient admissions and procedures (including surgeries and other complex interve...

Global Health Limited Financial Statement Overview

Summary
Strong multi-year revenue and earnings growth with a generally de-risked balance sheet, but the latest period shows a notable negative: free cash flow turned negative in 2026 and debt rose versus 2025, alongside some margin volatility.
Income Statement
82
Very Positive
Balance Sheet
74
Positive
Cash Flow
63
Positive
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue39.49B44.10B36.37B32.41B26.83B21.67B
Gross Profit30.12B20.95B27.57B24.82B20.58B16.24B
EBITDA9.84B9.19B9.05B8.72B6.77B4.90B
Net Income5.62B5.56B4.81B4.78B3.26B1.96B
Balance Sheet
Total Assets54.10B59.05B47.66B43.04B41.16B31.46B
Cash, Cash Equivalents and Short-Term Investments12.55B11.30B10.51B11.56B12.60B5.12B
Total Debt9.45B11.90B7.18B8.02B11.22B11.09B
Total Liabilities16.99B19.21B13.79B13.98B16.88B15.30B
Stockholders Equity37.08B39.62B33.86B29.06B24.28B16.16B
Cash Flow
Free Cash Flow-841.82M-2.25B1.07B3.33B4.09B367.87M
Operating Cash Flow3.29B7.53B6.24B6.12B6.45B3.11B
Investing Cash Flow464.62M-11.43B-7.21B-4.41B-3.42B-4.21B
Financing Cash Flow1.54B2.87B-972.26M-5.14B3.46B1.60B

Global Health Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1216.65
Price Trends
50DMA
1099.13
Positive
100DMA
1121.60
Positive
200DMA
1215.19
Positive
Market Momentum
MACD
40.14
Negative
RSI
64.91
Neutral
STOCH
74.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDANTA, the sentiment is Positive. The current price of 1216.65 is above the 20-day moving average (MA) of 1173.47, above the 50-day MA of 1099.13, and above the 200-day MA of 1215.19, indicating a bullish trend. The MACD of 40.14 indicates Negative momentum. The RSI at 64.91 is Neutral, neither overbought nor oversold. The STOCH value of 74.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MEDANTA.

Global Health Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
₹388.91B75.820.24%25.81%-0.76%
66
Neutral
₹333.70B46.410.04%19.44%15.55%
66
Neutral
₹1.16T50.390.27%14.52%37.54%
66
Neutral
₹1.05T84.460.14%24.44%40.69%
63
Neutral
₹395.95B61.580.84%12.20%-93.03%
61
Neutral
₹735.33B86.120.11%15.99%24.81%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:MEDANTA
Global Health Limited
1,241.20
60.28
5.10%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,098.65
1,131.98
16.25%
IN:ASTERDM
Aster DM Healthcare Ltd.
764.20
214.37
38.99%
IN:FORTIS
Fortis Healthcare Ltd.
974.00
302.40
45.03%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,076.30
-64.08
-5.62%
IN:NH
Narayana Hrudayalaya Ltd.
1,903.05
166.09
9.56%

Global Health Limited Corporate Events

Global Health Reports No Demat or Remat Activity for March Quarter
Apr 2, 2026
Global Health Limited has notified the stock exchanges that it has obtained the required quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 from its registrar and transfer agent, Kfin Technol...
Global Health Publishes Postal Ballot Voting Results and Scrutinizer’s Report
Mar 14, 2026
Global Health Limited, the operator of Medanta hospitals, is a listed Indian healthcare services company headquartered in New Delhi and focused on multi-specialty hospital care. It trades on both BSE and NSE under the symbol MEDANTA, serving patie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 15, 2026